Close Menu

Johns Hopkins

In PNAS this week: cell division rates decline with age, different genetic lineages of chytrid fungus found, and more.

The company said it has seen progress in efforts to get FDA approval for its tissue and liquid biopsy tests as data continues to accumulate for pan-cancer utility.

Researchers found that 14 percent of individuals with metastatic breast cancer had risky mutations germline mutations, including patients who did not meet testing criteria.

NanoView will develop custom antibody-based assays on its ExoView platform to identify EVs containing biomarkers potentially linked to the neurological disorders.

The team will create a group called the Extracellular RNA Communication Consortium Stage 2 to develop new EV-based technology and treat diseases.

The grant recipients will receive up to $5 million each and are led by scientists at institutions including Harvard Medical School and the Cleveland Clinic.

Researchers analyzed RNA sequencing data gathered from induced pluripotent stem cells as they differentiated into heart muscle cells.

Thrive Earlier Detection is banking on targeted detection of frequent cancer mutations, coupled with protein markers, while competitors turn to genome-wide approaches.

Never smokers make up an increasing portion of lung cancer patients, and researchers are working to tease out their genetic and environmental risk.

In Nature this week: Integrative Human Microbiome Project researchers investigate host-microbiome relationship in health and disease, and more.

Pages

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.